Scanogen square logo


pippeting hands background


Scanogen is a biotechnology and medical device start-up company founded in 2011. The company has developed  Single Molecule Scanning, a proprietary technology for rapid and ultra-sensitive detection of biomolecules. Scanogen is using this technology to develop point of care tests that will improve health care by providing easy and inexpensive access to the genetic information present in patient samples. The company has received NIH grants totalling over $6 million to develop its diagnostic assays. Scanogen is focused on three areas: Point-of-care detection of infectious diseases, blood infection detection and early cancer detection.

The company is located in Baltimore, Maryland. This is a privileged location to interact with some of the best biomedical researchers in the country at Johns Hopkins University and with  government agencies in Washington D.C (FDA, NIH, NIST).

Founder and CEO

Founder and CEO
Alfredo (Al) Celedon, Ph.D

Al discovered a novel method to detect biomolecules and encouraged by the potential of the new technology founded Scanogen. Al is leading the development of Single Molecule Scanning tests for the detection of infectious diseases and early diagnosis of cancer. He has established collaborations with researchers at the Johns Hopkins School of Medicine and has filed patents for 5 inventions. Before funding Scanogen, Al was a visiting professor at the Institute for BioNanotechnology at Johns Hopkins. Al holds a Ph.D from Johns Hopkins University and a Masters from University of California, Los Angeles.

Advisory Board

Arthur Colvin
Antony Newton
Arthur (Skip) Colvin

Antony Newton

Skip has over 35 years of experience in biotechnology and medical device product creation and development. Skip began his career at the startup of Life Technologies, then founded and served as President of Cerex Inc. Most recently Skip cofounded Senseonics, and is the inventor of the company's core technology. He has created and led the development of more than 40 products for the biotechnology, food processing, and medical device industries and holds nearly 70 issued and pending US patents not including international counterparts. He holds a BS in Biochemistry from the Virginia Polytechnic Institute with graduate studies in Biochemical Engineering at the University of Maryland and the Johns Hopkins University (APL)
Antony is a biotechnology industry veteran with over 25 years’ experience at companies including Amersham International (GE Life Sciences), Sigma- Aldrich and as a Vice President in Genzyme Oncology. Antony was part of a team that built the Genzyme Oncology business from conception to a ~$1BN commercial business and was responsible for a range of roles in program and portfolio management, alliances and collaborations.  Antony has a M.Sc. from Brunel University, London and a PG Dip (DMS) from Anglia Ruskin University, Cambridge.

William Bishai
Richard Hughen
William Bishai, M.D. Ph.D

Richard Hughen
William has been working on mycobacterium tuberculosis mechanisms of pathogenesis and novel drugs and drug targets for over 15 years. He has authored over 150 papers in peer reviewed journals. He serves on several editorial boards, review panels, and is the Co-Chair of the WHO Stop TB Partnership’s Working Group for New TB Drugs. He holds a M.D. and a Ph.D. from Harvard Medical School and was a Howard Hughes Postdoctoral Research Fellow in the laboratory of Nobel laureate, Dr. Hamilton Smith. He joined the Johns Hopkins faculty in 1994 and is currently a Professor of Medicine in the Dept. of Medicine and Co-Director of the JHU Center for TB research.
Ric has over twenty-five years of professional experience in the medical device businesses focusing on the commercialization process including product and market strategy, product development, product management, marketing and sales. He has successfully grown businesses in diverse environments including two startups, a mid-cap and three fortune 500 companies. Most recently Ric led CSA Medical as Vice President of Thoracic Surgery, Gastroenterology & Pulmonology. Previously he directed marketing strategy and operations for the $210M molecular diagnostics business of Becton Dickinson (BD). Previously, Ric led various management, marketing, training and sales teams for Johnson & Johnson and Abbott Diagnostics. Mr. Hughen has an MBA (marketing) and BS (Science) degree from The Pennsylvania State University.


William Bishai, M.D., Ph.D.  Co-Director of the Center for TB research at Johns Hopkins University School of Medicine.

Karen Carroll, M.D. Director of the Division of Medical Microbiology at Johns Hopkins University School of Medicine.

Michael Goggins, M.D. Director of the Pancreatic Cancer Early Detection Laboratory at Johns Hopkins University School of Medicine.

Richard Rothman, M.D., Ph.D.  Vice-Chair of Research, Emergency Medicine at Johns Hopkins University School of Medicine.


Point-of-care infection detection
Scanogen is developing a point-of-care platform for rapid and inexpensive detection of infectious diseases.  The test will make molecular diagnostics possible in small clinics, pharmacies and rural areas. A rapid TB test is under development in collaboration with Dr. William Bishai and Dr. Nikki Parrish.

Blood infection detection
Scanogen is developing diagnostic tests for the detection of pathogen and drug resistance in collaboration with Dr. Richard Rothman and Dr. Karen Carroll.

Early cancer detection
Scanogen is developing a test to screen for pancreatic cancer before symptoms appear, by detecting the presence of mutated DNA in blood and urine. The test is being developed in collaboration with Dr. Michael Goggins 


Scanogen has been funded with grants from the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, and the National Cancer Institute through its program Innovative Molecular Analysis Technologies.

IMAT logo
NHGRI logo
NCI logo
home link
2018 Scanogen Inc.

3102 Lord Baltimore Dr., Suite 214, Baltimore, MD, 21244 |